Sarepta Therapeutics Stock Price, News & Analysis (NASDAQ:SRPT) $87.03 -1.38 (-1.56%) (As of 12/8/2023 ET) Add Compare Share Share Today's Range$87.01▼$89.6550-Day Range$67.31▼$124.7652-Week Range$55.25▼$159.89Volume614,084 shsAverage Volume1.08 million shsMarket Capitalization$8.14 billionP/E RatioN/ADividend YieldN/APrice Target$153.10 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Sarepta Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.83 Rating ScoreUpside/Downside75.9% Upside$153.10 Price TargetShort InterestHealthy4.54% of Shares Sold ShortDividend StrengthN/ASustainability-1.65Upright™ Environmental ScoreNews Sentiment1.35Based on 7 Articles This WeekInsider TradingAcquiring Shares$5.94 M Bought Last QuarterProj. Earnings GrowthGrowingFrom ($6.90) to $0.98 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.90 out of 5 starsMedical Sector29th out of 942 stocksPharmaceutical Preparations Industry9th out of 445 stocks 4.4 Analyst's Opinion Consensus RatingSarepta Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 15 buy ratings, 3 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $153.10, Sarepta Therapeutics has a forecasted upside of 75.9% from its current price of $87.03.Amount of Analyst CoverageSarepta Therapeutics has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 4.0 Short Interest Percentage of Shares Shorted4.54% of the outstanding shares of Sarepta Therapeutics have been sold short.Short Interest Ratio / Days to CoverSarepta Therapeutics has a short interest ratio ("days to cover") of 2.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Sarepta Therapeutics has recently decreased by 4.49%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldSarepta Therapeutics does not currently pay a dividend.Dividend GrowthSarepta Therapeutics does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreSarepta Therapeutics has received a 62.32% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Neuromuscular disorders medication", "Clinical research services", and "Preclinical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Sarepta Therapeutics is -1.65. Previous Next 3.0 News and Social Media Coverage News SentimentSarepta Therapeutics has a news sentiment score of 1.35. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.51 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Sarepta Therapeutics this week, compared to 8 articles on an average week.Search Interest42 people have searched for SRPT on MarketBeat in the last 30 days. This is an increase of 17% compared to the previous 30 days.MarketBeat FollowsOnly 12 people have added Sarepta Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Sarepta Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $5,942,356.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 7.40% of the stock of Sarepta Therapeutics is held by insiders.Percentage Held by Institutions91.82% of the stock of Sarepta Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Sarepta Therapeutics are expected to grow in the coming year, from ($6.90) to $0.98 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Sarepta Therapeutics is -11.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Sarepta Therapeutics is -11.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSarepta Therapeutics has a P/B Ratio of 19.82. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Sarepta Therapeutics Stock (NASDAQ:SRPT)Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; and AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program that is under Phase 1/2a clinical trial; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Selecta Biosciences; Hansa Biopharma; Lysogene; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.Read More SRPT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SRPT Stock News HeadlinesDecember 9, 2023 | finance.yahoo.comCould Sarepta Therapeutics Stock Help You Become a Millionaire?December 6, 2023 | benzinga.comSarepta Therapeutics Stock (NASDAQ:SRPT), Short Interest ReportDecember 9, 2023 | DTI Trader (Ad)New CBOE “special perk” helps traders target income every weekendYou might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange. December 5, 2023 | morningstar.comSarepta Therapeutics Inc SRPTNovember 29, 2023 | finance.yahoo.comWall Street Analysts Think Sarepta Therapeutics (SRPT) Could Surge 82.64%: Read This Before Placing a BetNovember 27, 2023 | finance.yahoo.com11 Best Upside Stocks To Buy Right NowNovember 21, 2023 | msn.comWedbush Initiates Coverage of Sarepta Therapeutics (SRPT) with Outperform RecommendationNovember 20, 2023 | benzinga.comBig Players' Recent Trades in SRPT OptionsDecember 9, 2023 | DTI Trader (Ad)New CBOE “special perk” helps traders target income every weekendYou might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange. November 20, 2023 | finance.yahoo.com5 Biotechnology Stocks to Buy for a Stable Portfolio in 2024November 16, 2023 | finance.yahoo.comSolid Biosciences (SLDB) Stock Up as FDA Clears DMD Drug INDNovember 14, 2023 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Legend Biotech (LEGN), Ambu (OtherAMBFF) and Sarepta Therapeutics (SRPT)November 13, 2023 | finance.yahoo.comHere's Why Sarepta Therapeutics (SRPT) Is a Great 'Buy the Bottom' Stock NowNovember 11, 2023 | seekingalpha.comSarepta Therapeutics: Strong Q3 Earnings Help Offset Overblown Clinical Data ConcernsNovember 9, 2023 | finance.yahoo.comIs Sarepta Therapeutics Stock a Bad-News Buy?November 8, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Sarepta Therapeutics (SRPT), Adverum Biotechnologies (ADVM) and Alignment Healthcare (ALHC)November 8, 2023 | finance.yahoo.comInsider Spends US$3.9m Buying More Shares In Sarepta TherapeuticsNovember 8, 2023 | finance.yahoo.com1 Gene Therapy Stock to Buy and Hold for the Long HaulNovember 7, 2023 | finance.yahoo.comHere’s What Bronte Capital Calls “Sarepta Risk” in the Context of Sarepta Therapeutics (SRPT)November 7, 2023 | markets.businessinsider.comBank of America Securities Analyst Maintains Buy Rating for Sarepta Therapeutics Amid FDA Discussions and Potential Label ExpansionNovember 6, 2023 | benzinga.comDirector of Sarepta Therapeutics Purchased $3.94M In StockNovember 6, 2023 | benzinga.comSarepta Therapeutics President & CEO Makes $2.00M Stock PurchaseNovember 2, 2023 | msn.comSarepta Stock (NASDAQ:SRPT) Plunged 37% on Disappointing Elevidys Trial DataNovember 2, 2023 | finance.yahoo.comSarepta Therapeutics, Inc. (NASDAQ:SRPT) Q3 2023 Earnings Call TranscriptNovember 2, 2023 | finance.yahoo.comSarepta (SRPT) Q3 Loss Narrower Than Expected, Sales BeatNovember 2, 2023 | markets.businessinsider.comSarepta Therapeutics Q3 Earnings SummaryNovember 2, 2023 | finance.yahoo.comSarepta Therapeutics to Present at the UBS Biopharma ConferenceSee More Headlines Receive SRPT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sarepta Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/01/2023Today12/09/2023Fiscal Year End12/31/2023Next Earnings (Estimated)2/27/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SRPT Previous SymbolNASDAQ:AVII CUSIPN/A CIK873303 Webwww.sareptatherapeutics.com Phone(617) 274-4000Fax425-354-5038Employees1,162Year Founded1980Price Target and Rating Average Stock Price Target$153.10 High Stock Price Target$224.00 Low Stock Price Target$40.00 Potential Upside/Downside+75.9%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage18 Analysts Profitability EPS (Most Recent Fiscal Year)($7.83) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-703,490,000.00 Net Margins-62.52% Pretax Margin-59.89% Return on Equity-46.23% Return on Assets-9.69% Debt Debt-to-Equity Ratio1.62 Current Ratio5.44 Quick Ratio4.90 Sales & Book Value Annual Sales$933.01 million Price / Sales8.73 Cash FlowN/A Price / Cash FlowN/A Book Value$4.39 per share Price / Book19.82Miscellaneous Outstanding Shares93,550,000Free Float86,625,000Market Cap$8.14 billion OptionableOptionable Beta1.02 Social Links Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesMr. Douglas S. Ingram Esq. (Age 60)President, CEO & Director Comp: $1.62MMr. Ian Michael Estepan (Age 47)Executive VP & CFO Comp: $917.53kDr. Louise R. Rodino-Klapac Ph.D. (Age 45)Executive VP, Chief Scientific Officer and Head of Research & Development Comp: $1.04MMr. Ryan E. Brown J.D. (Age 45)Executive VP, General Counsel & Corporate Secretary Comp: $823.36kMr. Bilal Arif (Age 51)Executive VP & Chief Technical Operations Officer Ms. Francesca T. NolanExecutive Director of Investor Relations and Corporate CommunicationsMs. Alison NasisiExecutive VP & Chief People OfficerDr. Diane L. Berry Ph.D.Executive VP and Chief of Global Policy & Advocacy OfficerMr. Dallan MurrayExecutive VP & Chief Customer OfficerMr. Will TiltonSenior VP, Head of Strategy & Chief of StaffMore ExecutivesKey CompetitorsRoivant SciencesNASDAQ:ROIVVerona PharmaNASDAQ:VRNAKaruna TherapeuticsNASDAQ:KRTXImmunoGenNASDAQ:IMGNJazz PharmaceuticalsNASDAQ:JAZZView All CompetitorsInsiders & InstitutionsCitigroup Inc.Bought 20,000 shares on 12/6/2023Ownership: 0.000%Wellington Management Group LLPBought 54,698 shares on 12/1/2023Ownership: 4.179%Deutsche Bank AGSold 35,584 shares on 11/24/2023Ownership: 1.145%Walleye Trading LLCBought 9,500 shares on 11/21/2023Ownership: 0.000%Walleye Capital LLCSold 3,300 shares on 11/21/2023Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions SRPT Stock Analysis - Frequently Asked Questions Should I buy or sell Sarepta Therapeutics stock right now? 18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sarepta Therapeutics in the last year. There are currently 3 hold ratings and 15 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" SRPT shares. View SRPT analyst ratings or view top-rated stocks. What is Sarepta Therapeutics' stock price target for 2024? 18 equities research analysts have issued 1 year target prices for Sarepta Therapeutics' stock. Their SRPT share price targets range from $40.00 to $224.00. On average, they anticipate the company's share price to reach $153.10 in the next year. This suggests a possible upside of 75.9% from the stock's current price. View analysts price targets for SRPT or view top-rated stocks among Wall Street analysts. How have SRPT shares performed in 2023? Sarepta Therapeutics' stock was trading at $129.58 on January 1st, 2023. Since then, SRPT shares have decreased by 32.8% and is now trading at $87.03. View the best growth stocks for 2023 here. When is Sarepta Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 27th 2024. View our SRPT earnings forecast. How were Sarepta Therapeutics' earnings last quarter? Sarepta Therapeutics, Inc. (NASDAQ:SRPT) released its quarterly earnings results on Wednesday, November, 1st. The biotechnology company reported $0.37 EPS for the quarter, beating the consensus estimate of ($1.63) by $2.00. The biotechnology company had revenue of $331.80 million for the quarter, compared to analysts' expectations of $285.33 million. Sarepta Therapeutics had a negative trailing twelve-month return on equity of 46.23% and a negative net margin of 62.52%. The firm's revenue for the quarter was up 44.1% on a year-over-year basis. During the same quarter in the previous year, the company posted ($2.94) EPS. What ETFs hold Sarepta Therapeutics' stock? ETFs with the largest weight of Sarepta Therapeutics (NASDAQ:SRPT) stock in their portfolio include Morningstar US Small Growth (MSGR), Global X Genomics & Biotechnology ETF (GNOM), iShares Neuroscience and Healthcare ETF (IBRN), First Trust NYSE Arca Biotechnology Index Fund (FBT), Principal Healthcare Innovators ETF (BTEC), VanEck Biotech ETF (BBH), Franklin Genomic Advancements ETF (HELX) and American Century Mid Cap Growth Impact (MID). What is Douglas S. Ingram's approval rating as Sarepta Therapeutics' CEO? 15 employees have rated Sarepta Therapeutics Chief Executive Officer Douglas S. Ingram on Glassdoor.com. Douglas S. Ingram has an approval rating of 95% among the company's employees. This puts Douglas S. Ingram in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Sarepta Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Sarepta Therapeutics investors own include Intercept Pharmaceuticals (ICPT), NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Alibaba Group (BABA), Netflix (NFLX), Tesla (TSLA), AbbVie (ABBV) and Walt Disney (DIS). Who are Sarepta Therapeutics' major shareholders? Sarepta Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Wellington Management Group LLP (4.18%), Deutsche Bank AG (1.14%), Deutsche Bank AG (1.14%), Federated Hermes Inc. (1.03%), Westfield Capital Management Co. LP (0.86%) and Charles Schwab Investment Management Inc. (0.60%). Insiders that own company stock include Douglas S Ingram, Hans Lennart Rudolf Wigzell, Joseph Bratica, Louise Rodino-Klapac, M Kathleen Behrens, Michael Andrew Chambers, Richard Barry and Stephen Mayo. View institutional ownership trends. How do I buy shares of Sarepta Therapeutics? Shares of SRPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. Does Sarepta Therapeutics have any subsidiaries? The following companies are subsidiares of Sarepta Therapeutics: Eisai, Myonexus Therapeutics, ST International Holdings Two Inc., Sarepta Securities Corp., and Sarepta Therapeutics Three LLC.Read More This page (NASDAQ:SRPT) was last updated on 12/9/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sarepta Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.